Rankings
▼
Calendar
JAZZ Q2 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.0B
+2.1% YoY
Gross Profit
$929M
88.9% margin
Operating Income
-$686M
-65.6% margin
Net Income
-$718M
-68.7% margin
EPS (Diluted)
$-11.74
QoQ Revenue Growth
+16.5%
Cash Flow
Operating Cash Flow
$89M
Free Cash Flow
$101M
Stock-Based Comp.
$65M
Balance Sheet
Total Assets
$10.9B
Total Liabilities
$7.2B
Stockholders' Equity
$3.7B
Cash & Equivalents
$1.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.0B
$1.0B
+2.1%
Gross Profit
$929M
$914M
+1.7%
Operating Income
-$686M
$199M
-444.2%
Net Income
-$718M
$169M
-526.2%
Revenue Segments
Xywav
$415M
40%
Epidiolex/Epidyolex
$252M
24%
Rylaze/Enrylaze
$101M
10%
Zepzelca
$75M
7%
High Sodium AG Oxybate Product Royalty Revenue
$54M
5%
Defitelio/Defibrotide
$48M
5%
Vyxeos
$45M
4%
Xyrem
$35M
3%
Other Royalty And Contract Revenues
$6M
1%
Ziihera
$6M
1%
Sativex
$5M
0%
Other Products
$4M
0%
Geographic Segments
UNITED STATES
$936M
90%
Europe
$83M
8%
Other Countries
$27M
3%
← FY 2025
All Quarters
Q3 2025 →